SGLT2 Inhibition Updates 2021 - SGLT2 Inhibition in Cardiorenal Disease

Published: 20 July 2021

  • Views:

    Views Icon 25033

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Organised with scientific co-chairs Stefan Anker and Andrew Coats, this event includes presentations and panel discussions with a host of international thought-leaders. 

 

The SGLT2 Updates 2021 conference SGLT2 Inhibition in Cardiorenal Disease: Translating Evidence into Clinical Practice covers the place of SGLT2 inhibitors in the newly released guidelines of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) as well as their implementation in clinical practice.

 

In addition to plenary sessions and satellite symposia the conference featured a number of Meet The Expert breakout sessions discussing the implications in treatment of specific patient subgroups including patients with comorbidities.  Audience questions were submitted throughout and were addressed by the panel experts.

Educational Objectives

SGLT2 Inhibition in Cardiorenal Disease

  • Prepare cardiologists, nephrologists and endocrinologists to effectively manage patients with heart failure, individually and collaboratively
  • Apply findings from clinical trials into clinical practice
  • Describe the role of SGLT2 inhibitors in different patient subgroups, including patients with comorbidities
  • Evaluate the safety and cardiorenal benefits of glucose-lowering agents
  • Implement the new guidelines of the HFA of the ESC in clinical practice

Target Audience

  • Cardiologists
  • Nephrologists
  • Endocrinologists

More from this programme

Part 1

State of the Art 1

6 sessions
Welcome and Introduction Watch now
SGLT2 Inhibitors for Patients with Diabetes and an Increased CV Risk: How The Success Story Started Watch now
SGLT2 Inhibitors: Evolution from Glucose Lowering to Cardiorenal Protection Watch now
SGLT2 Inhibitors in Cardiology Indications: The Data Watch now
SGLT2 Inhibitors in Chronic Kidney Disease: The Data Watch now
Panel Discussion Watch now

Part 2

SGLT2 Inhibitors in Heart Failure: A Practical Approach

Industry Satellite Symposium supported by the Boehringer Ingelheim and Lilly alliance
4 sessions
Place of SGLT2 Inhibitors in the Heart Failure Treatment Algorithm Watch now
SGLT2 Inhibitors: Safety Considerations Watch now
How to Use SGLT2 Inhibitors in Daily Practice Watch now
Panel Discussion Watch now

Part 3

Meet The Expert: Implications for Clinical Practice - Breakout 1

Totality of Evidence for the Cardiorenal Patient - discussion with Alice Cheung and Andrew Coats. Session supported by an unrestricted grant from AstraZeneca
2 sessions
Totality of Evidence for the Cardiorenal Patient Watch now
Discussion Watch now

Part 4

Meet The Expert: Implications for Clinical Practice - Breakout 2

SGLT2i and QoL Improvement - discussion with Shelley Zieroth and John Spertus.
2 sessions
Welcome and Introduction Watch now
KCCQ Score Overview and Discussion Watch now

Part 5

Meet The Expert: Implications for Clinical Practice - Breakout 3

Age groups and vulnerable patients with Gerasimos Filippatos and Giuseppe Rosano.
3 sessions
Welcome and Introduction Watch now
SGLT2i in the Elderly and Vulnerable Patients Watch now
Discussion Watch now

Part 6

State of the Art 2

6 sessions
Welcome and Introduction Watch now
How do SGLT2 Inhibitors Bring About Cardiorenal Benefits? Watch now
Totality of Evidence in Heart Failure Watch now
Trial Results Coming Out Soon Watch now
Heart Failure Guidelines Watch now
Panel Discussion Watch now

Part 7

SGLT2 Inhibitors for Heart Failure: The New Standard of Care

Industry Satellite Symposium supported by the Boehringer Ingelheim and Lilly alliance
3 sessions
Welcome and Introduction Watch now
Keynote Lecture - SGLT2 Inhibitors for Heart Failure: The New Standard of Care Watch now
Panel Discussion Watch now

Part 8

Meet The Expert: Implications for Clinical Practice - Breakout 4

Early Treatment Initiation in the Hospital Setting - discussion with Marc Petrie and Deepak Bhatt. Session supported by an unrestricted grant from AstraZeneca
3 sessions
Welcome and Introduction Watch now
Soloist Trial Overview Watch now
Discussion Watch now

Part 9

Meet The Expert: Implications for Clinical Practice - Breakout 5

Managing Patients with Comorbidities (T2D & CKD) - discussion with Paola Fioretto and Katherine Tuttle. Session supported by an unrestricted grant from AstraZeneca
1 session
Managing Patients with Comorbidities (T2D & CKD) Watch now

Part 10

Meet The Expert: Implications for Clinical Practice - Breakout 6

Interdisciplinary Collaboration and Care Transitions - discussion with Subodh Verma. Session supported by an unrestricted grant from AstraZeneca
1 session
Interdisciplinary Collaboration and Care Transitions Watch now

Faculty Biographies

Milton Packer

Milton Packer

Distinguished Scholar in Cardiovascular Science

Personal History

Dr Milton Packer was born to Polish immigrants in 1951 and raised in Philadelphia, US. Prior to studying medicine, he was politically active in the 1960s. In his words: “The focus of my upbringing was education, but the major guiding principle in my childhood years (and throughout my entire life) was an uncompromising sense of justice. I was always imbued with the need to strive for and defend the truth.” He began his career in cardiology during a pivotal time for the field, just as interventional cardiology and

View full profile